

June 14, 2021

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: David Gessert

**Re: Verve Therapeutics, Inc.**  
**Registration Statement on Form S-1 (File No. 333-256608)**  
**Request for Acceleration**

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof, approximately 433 copies of the Preliminary Prospectus dated June 14, 2021 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement be accelerated to 4:00 p.m. Eastern Time, on June 16, 2021 or as soon thereafter as practicable.

*[Signature page follows]*

---

Very truly yours,

J.P. MORGAN SECURITIES LLC  
JEFFERIES LLC  
GUGGENHEIM SECURETIES, LLC  
WILLIAM BLAIR & COMPANY, L.L.C.

As representatives of the Underwriters

J.P. MORGAN SECURITIES LLC

By: /s/ David Ke  
Name: David Ke  
Title: Managing Director

JEFFERIES LLC

By: /s/ Dustin Tyner  
Name: Dustin Tyner  
Title: Managing Director

GUGGENHEIM SECURETIES, LLC

By: /s/ Thomas Burkly  
Name: Thomas Burkly  
Title: Senior Managing Director

WILLIAM BLAIR & COMPANY, L.L.C.

By: /s/ Rakhee Bhagat  
Name: Rakhee Bhagat  
Title: Managing Director, Equity Capital Markets

[Signature Page to Verve Therapeutics, Inc. Acceleration Request]